Literature DB >> 18140667

Antibody response of patients with poliomyelitis to virus recovered from their own alimentary tract.

A J STEIGMAN, A B SABIN.   

Abstract

Of 20 strains of virus recovered from 40 patients with poliomyelitis only 9 possessed a titer of 10(-3) or more, permitting significant quantitative neutralization tests in monkeys. Seven of the 9 high titer strains were derived from patients whose illness was ultimately paralytic, and tests with their undiluted sera indicated that the acute phase as well as the 3 month convalescent specimens neutralized maximum amounts of the patient's own virus. However when varying dilutions of the sera were tested against a single dose of virus, it was found that the antibody was present in lowest concentration early after onset and progressively increased in titer over a period of weeks during convalescence. The 2 remaining high titer strains were recovered from patients with a non-paralytic illness, and in both of these the acute phase sera were without significant amounts of antibody for their own virus. Antibody was demonstrable at 14, 28, and 92 days after onset in one of these patients, while the other had none at 1 month and only a minimal amount at 3 and 8 months. Tests with the Lansing virus on the same sera, clearly established the specificity of the antibody response to the strain of virus recovered from each patient under investigation. Five of the 9 patients, whose sera were studied with both viruses, had no antibody for the Lansing virus during the acute phase and none 3 months later. Two had antibody during the acute phase but serum dilution tests showed no increase in titer in the 3 month convalescent specimen. In 2 others, who were without antibody for the Lansing virus during the acute phase but had it at 3 months after onset, it was possible to show that this antibody appeared later than 1 month after the illness and that the virus recovered from these patients during their illness was not antigenically of the Lansing type.

Entities:  

Keywords:  POLIOMYELITIS/virus

Mesh:

Year:  1949        PMID: 18140667      PMCID: PMC2135911          DOI: 10.1084/jem.90.4.349

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

1.  NEUTRALIZATION TESTS IN POLIOMYELITIS. SERA TAKEN DURING THE ACUTE AND CONVALESCENT STAGES OF THE DISEASE AND TESTED WITH A PASSAGE VIRUS AND A STRAIN ISOLATED DURING THE 1935 NEW YORK CITY OUTBREAK.

Authors:  M Brodie; A E Fischer; M Stillerman
Journal:  J Clin Invest       Date:  1937-05       Impact factor: 14.808

2.  Serum neutralizing antibodies to the infecting strain of virus in poliomyelitis patients.

Authors:  W M HAMMON; E C ROBERTS
Journal:  Proc Soc Exp Biol Med       Date:  1948-11

3.  Antibody response in monkeys following oral administration of poliomyelitis virus.

Authors:  H VON MAGNUS; J L MELNICK
Journal:  J Immunol       Date:  1948-12       Impact factor: 5.422

4.  POLIOMYELITIS IN A LABORATORY WORKER EXPOSED TO THE VIRUS.

Authors:  A B Sabin; R Ward
Journal:  Science       Date:  1941-08-01       Impact factor: 47.728

5.  NATURE OF NON-PARALYTIC AND TRANSITORY PARALYTIC POLIOMYELITIS IN RHESUS MONKEYS INOCULATED WITH HUMAN VIRUS.

Authors:  A B Sabin; R Ward
Journal:  J Exp Med       Date:  1941-05-31       Impact factor: 14.307

6.  THE NEUTRALIZATION TEST IN POLIOMYELITIS : COMPARATIVE RESULTS WITH FOUR STRAINS OF THE VIRUS.

Authors:  J R Paul; J D Trask
Journal:  J Exp Med       Date:  1935-03-31       Impact factor: 14.307

7.  HUMORAL ANTIBODIES AND RESISTANCE OF VACCINATED AND CONVALESCENT MONKEYS TO POLIOMYELITIS VIRUS.

Authors:  A B Sabin; P K Olitsky
Journal:  J Exp Med       Date:  1936-10-31       Impact factor: 14.307

8.  NEUTRALIZING ANTIBODIES IN ABORTIVE POLIOMYELITIS.

Authors:  J D Trask; J R Paul
Journal:  J Exp Med       Date:  1933-10-31       Impact factor: 14.307

9.  THE NATURAL HISTORY OF HUMAN POLIOMYELITIS : II. ELIMINATION OF THE VIRUS.

Authors:  A B Sabin; R Ward
Journal:  J Exp Med       Date:  1941-11-30       Impact factor: 14.307

  9 in total
  12 in total

1.  [Additional data on the incidence of Coxsackie virus infection in Germany].

Authors:  W KELLER; O VIVELL
Journal:  Klin Wochenschr       Date:  1952-04-01

2.  Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.

Authors:  J CASALS; P K OLITSKY; A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

3.  Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.

Authors:  A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

4.  Homotypic complement-fixing antibody in monkeys infected with type 2 poliomyelitis virus by the oral route.

Authors:  J CASALS; P K OLITSKY; A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

5.  Immunological reactions of the Coxsackie viruses. II. The complement fixation test.

Authors:  L M KRAFT; J L MELNICK
Journal:  J Exp Med       Date:  1950-11-01       Impact factor: 14.307

6.  Viremia in human poliomyelitis.

Authors:  D M HORSTMANN; R W McCOLLUM; A D MASCOLA
Journal:  J Exp Med       Date:  1954-04-01       Impact factor: 14.307

7.  Ohio strains of a virus pathogenic for infant mice, Coxsackie group; simultaneous occurrence with poliomyelitis virus in patients with summer grippe.

Authors:  J L MELNICK; N LEDINKO
Journal:  J Exp Med       Date:  1950-02       Impact factor: 14.307

8.  Poliomyelitis in chimpanzees; studies in homologous and heterologous immunity following inapparent infection.

Authors:  D M HORSTMANN; J L MELNICK
Journal:  J Exp Med       Date:  1950-06-01       Impact factor: 14.307

9.  Levels of homotypic neutralizing antibody in human poliomyelitis three years after infection.

Authors:  J WINSSER; A B SABIN
Journal:  J Exp Med       Date:  1952-11       Impact factor: 14.307

10.  A specific complement-fixation test for infection with poliomyelitis virus.

Authors:  J CASALS; P K OLITSKY; R O ANSLOW
Journal:  J Exp Med       Date:  1951-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.